Five Prime cuts 41 jobs, days be­fore pre­sent­ing da­ta at AS­CO meet­ing of GI can­cers

Things have not been the same at can­cer-fo­cused drug de­vel­op­er Five Prime Ther­a­peu­tics $FPRX since late 2017, when its Bris­tol-My­ers $BMY part­nered drug cabi­ral­izum­ab in com­bi­na­tion with Op­di­vo showed signs of weak ef­fi­ca­cy and a trou­bling safe­ty pro­file in an ear­ly-stage pan­cre­at­ic can­cer tri­al. On Tues­day, the com­pa­ny said it had cut 41 jobs to fo­cus its re­sources on its late-stage pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER